CD40LG and acute kidney injury: Thus, we expect that AIM administration or artificial activation of AIM, for example by induction of release of AIM from IgM by small-molecule therapeutics, can be clinically applied for therapy of appropriate diseases such as AKI and fungal peritonitis, and other injury- or inflammation-associated diseases.